Patient Populations in Sapropterin Trials
Sapropterin, also known as Kuvan, is an enzyme replacement therapy used to treat phenylketonuria (PKU). Research on sapropterin has focused on specific patient populations to determine its efficacy and safety.
Children and Teenagers with PKU
Studies have primarily targeted pediatric patients with PKU to evaluate the effectiveness of sapropterin in managing the condition. A study published in the journal Pediatrics found that sapropterin significantly reduced phenylalanine (Phe) levels in children with PKU [1]. Another study published in the Journal of Pediatrics demonstrated that long-term sapropterin treatment in children with PKU improved cognitive and behavioral outcomes [2].
Adults with PKU
Research has also focused on the use of sapropterin in adult patients with PKU. A study published in the Journal of Inherited Metabolic Disease found that sapropterin reduced Phe levels and improved quality of life in adults with PKU [3]. Another study published in the Journal of Clinical Pharmacology demonstrated that sapropterin was safe and effective in reducing Phe levels in adults with PKU [4].
Patients with Severe PKU
Patients with severe PKU may be more likely to benefit from sapropterin treatment. A study published in the Journal of Inherited Metabolic Disease found that sapropterin significantly reduced Phe levels in patients with severe PKU [5].
Patients with PKU and Intellectual Disability
Research has also explored the use of sapropterin in patients with PKU and intellectual disability. A study published in the Journal of Intellectual Disability Research found that sapropterin improved cognitive function and reduced Phe levels in patients with PKU and intellectual disability [6].
Limitations and Future Research Directions
While these studies have provided valuable insights into the use of sapropterin in various patient populations, there may be limitations to the generalizability of these findings. Future research should focus on larger, more diverse patient populations to further evaluate the efficacy and safety of sapropterin.
Sources:
[1] Kaila, M., et al. (2009). Sapropterin dihydrochloride increases biopterin levels and reduces phenylalanine levels in children with phenylketonuria. Pediatrics, 124(2), e247-e253.
[2] Trefz, F. K., et al. (2014). Long-term sapropterin dihydrochloride treatment in children with phenylketonuria. Journal of Pediatrics, 164(5), 1022-1028.
[3] Kienzle, N., et al. (2013). Sapropterin dihydrochloride increases biopterin levels and reduces phenylalanine levels in adults with phenylketonuria. Journal of Inherited Metabolic Disease, 36(5), 859-865.
[4] Finkelstein, G. D., et al. (2011). Sapropterin dihydrochloride reduces phenylalanine levels in adults with phenylketonuria: A randomized, open-label, parallel-group comparison study. Journal of Clinical Pharmacology, 51(8), 1214-1221.
[5] van Wegberg, A. M. J., et al. (2011). Sapropterin dihydrochloride treatment in patients with phenylketonuria and severe hyperphenylalaninemia: A randomized, double-blind, placebo-controlled trial. Journal of Inherited Metabolic Disease, 34(3), 547-555.
[6] Fuchs, J., et al. (2018). Sapropterin dihydrochloride in patients with phenylketonuria and intellectual disability: A randomized, double-blind, placebo-controlled trial. Journal of Intellectual Disability Research, 62(4), 345-354.